EULAR 2021 - RA Congress Preview

Enhancing knowledge of the clinical
importance of cytokine signalling
The Cytokine Signalling Forum
www.cytokinesignalling.com
EULAR 2021
Congress Preview
Rheumatoid Arthritis
Register for FREE content at www.cytokinesignalling.com
DEVELOPED UNDER
THE AUSPICES OF THE
Follow us at:
Cytokine Signalling Forum

Chairman’s Introduction
Dear CSF Member,
Welcome to this year’s selection of EULAR abstracts on cytokine signalling agents available for use in RA and my
‘Chairman’s Picks’. Every year the amount of data concerning these agents continues to increase, and so, for this year’s
EULAR we have again focused our selections herein only on RA, with other indications addressed in a separate review.
There are several abstracts featuring upadacitinib. Key among them are the 3-year results from the SELECT-EARLY
trial [POS0655], and the 4.5-year integrated laboratory abnormality profiles of upadacitinib from the phase 3 SELECT
program [OP0128]. Treatment effectiveness of upadacitinib in US patients from the United Rheumatology NICE TM
Real-World Data [POS0666] will be presented, along with patient characteristics and outcomes in patients treated with
upadacitinib from the OM1 RA registry [POS0436]. There is an interesting analysis on the impact of glucocorticoids on
the efficacy and safety of upadacitinib [POS0654], and the relationship between changes in lipid level improvements in
disease activity outcomes [POS0656]. In addition, Martin Bergman and colleagues assess the RAPID 3 in patients with
long term upadacitinib therapy [POS0670].
Turning to baricitinib, Gilbert et al presents an update to the real-world effectiveness of baricitinib in the Swiss RA
register (SCQM-RA) [POS0668]. There is an analysis of the Power Doppler Ultrasound study assessing the rapid
response to baricitinib in RA patients with an inadequate response to MTX and one bDMARD [POS0661]. There are
also two abstracts presenting improvements in PROs, the first by Taylor et al, looking at PROs across all disease
activity levels comparing baricitinib to placebo and adalimumab [POS0649], and the second by Strand et al, highlighting
the rapid and concurrent PRO improvements in RA with baricitinib in RA-BEAM [POS0646]. Finally, there will also be a
real-world direct comparison of effectiveness and safety of tofacitinib and baricitinib by Iwamoto and colleagues.
For filgotinib, Emery et al. demonstrates the clinical efficacy of filgotinib in RA independent of smoking status
[POS0536]. Whilst Galloway et al are presenting the infections and serious infections in the filgotinib rheumatoid arthritis
program [OP0126].
In tofacitinib there is an analysis on RA associated interstitial lung disease from the Treasure Real-Life data [OP0125].
There are two abstracts looking at the discontinuation rates of tofacitinib using pooled data from two RA registries in
Canada. The first compares tofacitinib with TNFi [OP0179], and the second compares tofacitinib monotherapy with
combination therapy with MTX [POS0448].
At this year’s congress, there is a great selection of symposia to keep an eye on. Pfizer looking at JAK inhibitors in RA,
along with Lilly that explores the global experience of treating RA with baricitinib. AbbVie will be presenting the session
on remission with JAK inhibition, and Galapagos will bring us two symposia walking “In Darwin’s Footsteps”. This year
we are delighted to present a CSF symposium – supported by Lilly - looking at the cytokine signalling pathways,
and the immune-pathologic consequences of targeting those pathways.
Within the following pages, we share our detailed selection of the congress highlights. As always, thank you for your
continued support, and we hope you enjoy the virtual EULAR 2021 experience.
Kind regards,
Prof. Iain McInnes
Chairman’s picks

Key Presentations
Wednesday, June 2, 2021
POSTERS
POS0668 Real World Effectiveness of Baricitinib In the Swiss
Rheumatoid Arthritis Register (SCQM-RA)
POS0631 Comparative Efficacy of Combination Therapy with
Biologic or Target Synthetic Drugs for Rheumatoid
Arthritis: A Bayesian Network Meta-Analysis.
POS0661 Rapid Response to Baricitinib In Patients with
Rheumatoid Arthritis and An Inadequate Response
to Methotrexate And At Least One Biologic DMARD:
A Clinical and Power Doppler Ultrasound Study
POS0606 Disease Activity and Patients-Reported Outcomes
After Switching Between IL-6 Receptor Inhibitors
and JAK Inhibitors: An Analysis from the Corrona
Registry
POS0450 Incidence Rates of Difficult-to-treat Rheumatoid
Arthritis in Real-world Clinical Practice
POS0666 Treatment Effectiveness of Upadacitinib at 3
Months in US Patients with Rheumatoid Arthritis
from The United Rheumatology Normalized
Integrated Community Evidence (NICE TM )
Real-World Data
POS0667 Tofacitinib in Patients with Rheumatoid Arthritis in
Real-World Settings: A National Multicenter Study
of 167 Patients from Argentina
SATELLITE SYMPOSIA
Pfizer
JAK Inhibitors in RA: What, Where, How, Why,
Who and When?
Industry Room 1, 18:15–19:45
Speakers: Gerd Rüdiger Burmester, Elizabeth Perkins,
Hendrik Schulze-Koops, and Ai Lyn Tan
AbbVie
A Practical Guide to Use of JAK Inhibitors in the
Management of RA and SpA
Industry Room 2, 18:15–19:45
Speakers: Maya H Buch, Andrea Rubbert-Roth,
Andrew Ostor, and Janet Pope
Lilly
Exploring Global Olumiant Experience in Treating
Rheumatoid Arthritis: Different Continents,
Different Circumstances
Industry Room 7, 18:15–19:45
Speakers: Roberto Caporali, Peter C. Taylor, and Rieke Alten
Galapagos
In Darwin’s Footsteps: Continuing Evolution of RA
Patient Care as we Adapt to a Changing Environment
Industry Room 10, 18:15–19:45
Speakers: Laure Gossec, Peter C. Taylor, and Peter Nash
Chairman’s picks

Thursday, June 3, 2021
ORAL PRESENTATIONS
Rheumatoid Arthritis – Biological DMARDs
Room 4, 10:15–11:45
Chair: Hanna W. van Steenbergen
Online Moderator: Reinhard Bos
OP0114
OP0116
Short- And Longer-Term Risks for Acute Coronary
Syndrome in Patients with Rheumatoid Arthritis
Starting Treatment with Disease-Modifying
Anti-Rheumatic Drugs. A Collaborative
Observational Head-To-Head Study Across Five
Nordic Rheumatology Registers
Elderly Patients are Not at Increased Risk of
Serious Infections When Receiving bDMARDs or
JAK Inhibitors Compared To csDMARD Treatment
Rheumatoid Arthritis – Non-Biologic Treatment and
Small Molecules
Room 5, 10:15–11:45
Chair: Carlo Perricone
Online Moderator: Rorberto Giacomelli
OP0122
OP0123
OP0125
OP0126
OP0128
Comparative Effectiveness of JAKi Versus
bDMARDs; a Nationwide Study in RA
Safety Profile of JAK-Inhibitors Versus TNF-
Inhibitors in Real-World Clinical Practice:
Data from A Multicenter Register
Tofacitinib in Rheumatoid Arthritis-Associated
Interstitial Lung Disease: Efficacy and Safety
Analysis from Treasure Real-Life Data
Infections and Serious Infections in the Filgotinib
Rheumatoid Arthritis Program
Integrated Laboratory Abnormality Profiles of
Upadacitinib with Up To 4.5 Years of Exposure in
Patients with Rheumatoid Arthritis Treated in the
SELECT Phase 3 Program
Rheumatoid Arthritis – Prognosis, Predictors
and Outcome
Room 13, 10:15–11:45
Chair: Martin Aringer
Online Moderator: Alexandre Sepriano
OP0179
Discontinuation Rate of Tofacitinib Is Similar When
Compared to TNF Inhibitors in Rheumatoid Arthritis
Patients: Pooled Data from Two Rheumatoid
Arthritis Registries in Canada
OP0182
OP0183
In RA Patients in Remission, Which Biomarkers
Predict Successful Tapering of csDMARDs?
Identification of A Subgroup of People with
Rheumatoid Arthritis Characterised by High Disability
Over 10 Years, Despite Low Inflammation: Results
from Two European Prospective Cohort Studies
MEET THE EXPERT
Pfizer
Personalising Patient Care: Reflections on the Place
of JAK Inhibitors in Rheumatology
Industry Room 1, 15:00–15:30
Speakers: Gerd Rüdiger Burmester and Laura Coates
AbbVie
Optimizing disease outcomes with the use of JAK
inhibitors in the management of RA and SpA:
An interactive clinical case discussion
Industry Room 2, 15:00–15:30
Speakers: Andrea Rubbert-Roth, Andrew Ostor, Janet Pope,
and Maya H Buch
CSF (Supported by Lilly)
How to Provide Patients Remission They Can Feel?
Industry Room 5, 15:00–15:30
Speakers: Hendrik Schulze-Koops and Bernard Combe
POSTERS
POS0436 Patient Characteristics and Outcomes in
Patients with Rheumatoid Arthritis Treated with
Upadacitinib: The OM1 RA Registry
POS0526 Sexual Function in Male and Female Patients with
Rheumatoid Arthritis: A Post-Hoc Analysis of The
FINCH Studies
POS0649 Baricitinib Provides Greater Improvements in
Patient-Reported Outcomes Across All Disease
Activity Levels Compared to Placebo and
Adalimumab in Rheumatoid Arthritis
POS0669 Hypoglycaemia Following JAK Inhibitor Treatment in
Diabetes Mellitus Patients with Rheumatoid Arthritis
POS0670 Routine Assessment of Patient Index Data 3
(RAPID3) In Patients with Rheumatoid Arthritis
Treated with Long-Term Upadacitinib Therapy
Chairman’s picks

POS0671 Clinical Responses to Upadacitinib Or Abatacept In
Patients with Rheumatoid Arthritis by Type of Prior
Biologic Disease-Modifying Antirheumatic Drug:
Data from The Phase 3 SELECT-CHOICE Study
POS0536 Filgotinib Demonstrates Clinical Efficacy in
Rheumatoid Arthritis Independent of Smoking
Status: A Post-Hoc Subgroup Analysis of Three
Phase 3 Clinical Trials
POS0539 Pain Is an Independent Associated Factor on
Functional Limitation in Chinese Patients with
Early Rheumatoid Arthritis
SATELLITE SYMPOSIA
Galapagos
In Darwin’s Footsteps: Exploring the Role of JAK
Inhibitors within the Diverging RA Treatment
Landscape
Industry Room 4, 17:30–19:00
Speakers: Maxime Dougados, Rieke Alten, Kevin Winthrop,
and Ernest Choy
Friday, June 4, 2021
SATELLITE SYMPOSIA
AbbVie
Striving for Remission with JAK inhibition in the
Management of Rheumatoid Arthritis
Industry Room 7, 08:15–09:45
Speakers: Gerd Rüdiger Burmester, Philip G Conaghan,
Hendrik Schulze-Koops, and Grace C. Wright
MEET THE EXPERT
AbbVie
Rapid Fire Rheumatology: 20 Questions in 20 Min
with Prof Maya Buch
Industry Room 2, 15:00–15:30
Speaker: Maya Buch
SCIENTIFIC
tsDMARD Therapy of Rheumatoid Arthritis
Room 2, 15:30–17:00
Chair: Ernest Choy and Andrea Rubbert-Roth
Online Moderator: Hendrik Schulze-Koops
EULAR
EULAR
EULAR
JAKi in the News – Side Effects
“Selective” JAKi on the Verve – Implications for
Therapy
Ten years of JAKi in RA – Real Life Data from the
SCQM Registry
Managing Chronic Pain
Room 5, 15:30–17:00
Chair: Jon Lampa
Online Moderator: John McBeth
Case 1: Managing chronic pain in hand osteoarthritis
Speaker: Malvika Gulati
Discussion: Optimising pain management in osteoarthritis:
mechanism-based treatment strategies
Speaker: Tuhina Neogi
Case 2: Managing chronic pain in Rheumatoid Arthritis
Speaker: Rudresh Shukla
Discussion: Stratified targeted treatment strategies for
chronic pain in Rheumatoid Arthritis
Speaker: Neil Basu
POSTERS
POS0674 Direct Comparison of Effectiveness and Safety
of Tofacitinib and Baricitinib In Patients with
Rheumatoid Arthritis in Real-World Settings
POS0676 Survival of The First Course of Biologic or JAK
Inhibitor in Rheumatoid Arthritis: Association
with the Choice of Agent and Concomitant
Conventional Synthetic DMARDs
SATELLITE SYMPOSIA
CSF (Supported by Lilly)
Cytokine Signalling Blockade: Interactions and Outcomes
Industry Room 8, 17:30–19:00
Speakers: Paul Emery, John O’Shea, John Isaacs,
and Rieke Alten
Chairman’s picks

Saturday, June 5, 2021
POSTERS
POS0653 Impact of Upadacitinib or Adalimumab as Initial
Therapy on the Achievement of 48-Week Treatment
Goals in Patients with Rheumatoid Arthritis and
Inadequate Response to Methotrexate: Post hoc
Analysis of a Phase 3 Study
POS0654 Impact of Concomitant Glucocorticoids on the
Clinical Efficacy and Safety of Upadacitinib in
Patients with Rheumatoid Arthritis: An Ad Hoc
Analysis of Data from Three Phase 3 Studies
POS0655 Long-Term Safety and Efficacy of Upadacitinib in
Patients with Rheumatoid Arthritis: 3-Year Results
from the SELECT-EARLY Study
POS0594 Meaningful Improvement and Worsening in
Patients Who Do Not Achieve LDA and Switch
Therapy to a New Biologic or Targeted Therapy:
Results from the CORRONA Registry
POS0656 Relationship between Changes in Lipid Levels
and Improvement in Disease Activity Outcomes
in Patients with Rheumatoid Arthritis Receiving
Upadacitinib Treatment: Pooled Analysis of Data
from Two Phase 3 Studies
POS0646 Rapid and Concurrent Improvements in Patient-
Reported Outcomes of Rheumatoid Arthritis with
Baricitinib in RA-BEAM
POS0659 Real World Experience with Tofacitinib in Patients
with Rheumatoid Arthritis: An Interim Analysis
from a French Prospective Observational Study
DeFactTo
POS0448 Discontinuation Rate of Tofacitinib as Monotherapy
is Similar Compared to Combination Therapy with
Methotrexate in Rheumatoid Arthritis Patients:
Pooled Data from two Rheumatoid Arthritis
Registries in Canada
Chairman’s picks

SPONSORSHIP AND
UNRESTRICTED EDUCATIONAL
GRANTS FROM
IN PARTNERSHIP
WITH
Register for FREE content at www.cytokinesignalling.com
DEVELOPED UNDER
THE AUSPICES OF THE
Follow us at:
Cytokine Signalling Forum